For many people with Type 1 diabetes, Lantus has been a godsend, a long-acting, slow-release basal insulin that has helped thousands of people achieve better glycemic control. Since Lantus hit the market at the turn of the 21st century, it has also become a goldmine for its parent company, Sanofi, racking up nearly $8 billion in sales in 2013 alone.